Bias in nucleotide composition of antisense oligonucleotides

Antisense and Nucleic Acid Drug Development

Volumn 6, Issue 1, 1996, Pages 63-67

  Smetsers, Toon F C M ^a   Boezeman, Jan B M ^a   Mensink, Ewald J B M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA;

ARTICLE; DATA BASE; DRUG DESIGN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; RNA SEQUENCE;

EID: 0029998274     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1996.6.63     Document Type: Article

References (15)

1. BARTON, C.M., and LEMOINE, N.R. (1995). Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br. J. Cancer 71, 429-437.
2. BENNETT, C.F., CHIANG, M.Y., WILSONLINGARDO, L., and WYATT, J.R. (1994). Sequence-specific inhibition of human type II phospholipase A(2) enzyme activity by phosphorothioate oligonucleotides. Nucleic Acids Res. 22, 3202-3209.
3. BERGAN, R., CONNELL, Y., FAHMY, B., KYLE, E., and NECKERS, L. (1994). Aptameric inhibition of p210(bcr-abl) tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res. 22, 2150-2154.
4. BERGAN, R.C., KYLE, E., and NECKERS, L. (1995). Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res. Dev. 5, 33-38.
5. BUCKHEIT, R.W.J.R., ROBERSON, J.L., LACKMAN-SMITH, C., WYATT, J.R., VICKERS, T.A., and ECKER, D.J. (1994). Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Human Retroviruses 10, 1497-1506.
6. BURGESS, T.L., FISHER, E.F., ROSS, S.L., BREADY, J.V., QIAN, Y., BAYEWITCH, L.A., COHEN, A.M., HERRERA, C.J., HU, S.S., KRAMER, T.B., LOTT, F..D., MARTIN, F.H., PIERCE, G.F., SIMONET, L., and FARRELL, C.L. (1995). The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA 92, 4051-4055.
7. KOZAK, M. (1987). An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15, 8125-8148.
8. KRIEG, M.K., YI, A., MATSON, S., WALDSCHMIDT, T.J., BISHOP, D.A., TEASDALE, R., KORETZKY, G.A., and KLINMAN, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
9. MORI, K., BOIZIAU, C., CAZENAVE, C., MATSUKURA, M., SUBASINGHE, C., COHEN, J.S., BRODER, S., TOULME, J.J., and STEIN, C.A. (1989). Phosphoroselenoate oligodeoxynucleotides: Synthesis, physicochemical characterization, anti-sense inhibitory properties and anti-HIV activity. Nucleic Acids Res. 17, 8207-8219.
10. OJWANG, J., OKLEBERRY, K.M., MARSHALL, H.B., VU, H.M., HUFFMAN, J.H., and RANDO, R.F. (1994). Inhibition of Friend murine leukemia virus activity by guanosine/thymidine oligonucleotides. Antiviral Res. 25, 27-41.
11. SMETSERS, T.F.C.M., VAN-DE-LOCHT, L.T.F., PENNINGS, A.H.M., WESSELS, H.M., DE-WITTE, T.M., and MENSINK, E.J.B.M. (1995). Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 9, 118-130.
12. STEIN, C.A., and CHENG, Y.C. (1993). Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261, 1004-1012.
13. STEIN, C.A., and KRIEG, A.M. (1994). Problems in intepretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleolides. Antisense Res. Dev. 4, 67-69.
14. STEIN, C.A., MATSUKURA, M., SUBASINGHE, C., BRODER, S., and COHEN, J.S. (1989). Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. AIDS Res. Human Retroviruses 5, 639-646.
15. WYATT, J.R., VICKERS, T.A., ROBERSON, J.L., BUCKHEIT, R.W.J.R., KLIMKAIT, T., DEBAETS, E., DAVIS, P.W., RAYNER, B., IMBACH, J.L., and ECKER, D.J. (1994). Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. USA 91, 1356-1360.